Drug intelligence / Profile preview

Lactobacillus casei CAAS36

Development stage: Preclinical
Lead developer: Institute of Food Science and Technology, Chinese Academy of Agricultural Science
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus casei CAAS36 is a specific probiotic strain being studied for its potential to treat hyperlipidemia. [1-1] It was isolated from traditional homemade dairy products in Inner Mongolia, China. [1-19, 1-15] As a probiotic, it is believed to work by modulating the composition and metabolic pathways of the gut microbiota. [1-15] In preclinical studies, administration of L. casei CAAS36 resulted in significant reductions in key lipid markers, including a 29.9% decrease in total cholesterol, a 29.4% decrease in LDL-C, and a 32.6% decrease in triglycerides. [1-4] The research is being conducted by academic institutions in China, and there is currently no commercial developer or brand name associated with this strain.

Targets

MRC1 (Mannose Receptor C-type 1)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Lactobacillus casei CAAS36.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus casei CAAS36.

Explore the full profile